{
  "pmcid": "11878355",
  "sha256": "3e52801416f2e977290976fac491a09345bf028d697775532732f71da722bea1",
  "timestamp_utc": "2025-11-09T23:21:49.889485+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 11.880541841004185,
    "reading_ease": 31.169348326359852,
    "word_count": 239
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial Comparing Palonosetron and Ondansetron for PONV Prophylaxis"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "This randomised controlled trial included patients undergoing non-laparoscopic surgeries."
      },
      "Participants": {
        "score": 2,
        "evidence": "This randomised controlled trial included patients undergoing non-laparoscopic surgeries."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were randomly assigned to receive either intravenous palonosetron or ondansetron for PONV prophylaxis."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aims to compare the efficacy and safety of palonosetron and ondansetron in preventing PONV in non-laparoscopic surgeries."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the incidence of nausea and vomiting at postoperative time points: 0–2 hours, 0–6 hours, 12–24 hours, 24–48 hours, and 24–72 hours."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, and allocation was concealed."
      },
      "Blinding": {
        "score": 3,
        "evidence": "Blinding was applied to outcome assessors, patients, and clinicians."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "A total of 1681 participants were randomised: 842 to palonosetron and 839 to ondansetron."
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "The analysis was conducted using an intention-to-treat approach."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The pooled risk ratio (RR) for nausea at 12–24 hours was 0.39 (95% CI: 0.16, 0.96), and for vomiting at 24–48 hours was 0.24 (95% CI: 0.09, 0.62)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were mild and occurred with similar frequency in both groups."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: PROSPERO CRD42023426785."
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 24,
    "max_score": 25
  }
}